Introduction: Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and
lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial …

Introduction Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and
lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial …

Introduction: Imatinib is approved for the treatment of chronic myeloid leukemia and for
gastro intestinal stromal tumors. It is generally well tolerated with mild common toxicities …

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms that may affect
any portion of the gastrointestinal tract. Surgical resection was previously considered the …

The patient was a 64-year-old woman who had undergone partial enterectomy for a small
intestinal tumor in August 2005, and gastrointestinal stromal tumor (GIST) was diagnosed …

We report 2 cases of successful reintroduction of mesylate imatinib for gastrointestinal
stromal tumor (GIST) after drug-induced pneumonitis. Both of them were women in the fifth …

Background Imatinib mesylate has been used for the treatment of unresectable or metastatic
gastrointestinal stromal tumors (GIST). The current recommended dose of imatinib is 400 …

Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to
6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has …

Interstitial pneumonitis related to imatinib (Glivec) shows various radiological patterns but
usually improves after imatinib withdrawal or subsequent corticosteroid treatment (1-4) …

Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the digestive tract. The clinical
behavior of GISTs varies greatly, has extended follow-up, and almost all of the tumors have …